NASDAQ$VTYX
Ventyx Biosciences Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Ventyx Biosciences reported its fourth quarter and full year 2024 financial results, highlighting recent corporate progress and pipeline updates.
Ventyx Biosciences reported a net loss of $29.4 million for Q4 2024, an improvement from the $46.8 million net loss in Q4 2023. The company's cash, cash equivalents, and marketable securities stood at $252.9 million as of December 31, 2024, which is expected to fund operations into at least H2 2026. R&D expenses decreased significantly to $24.8 million from $42.0 million in the prior year.
- Net loss for Q4 2024 was $29.4 million, an improvement compared to $46.8 million in Q4 2023.
- Cash, cash equivalents, and marketable securities totaled $252.9 million as of December 31, 2024, providing funding into at least H2 2026.
- Research and Development (R&D) expenses decreased to $24.8 million in Q4 2024 from $42.0 million in Q4 2023.
- Topline data readouts from multiple Phase 2 studies, including VTX2735 in recurrent pericarditis and VTX3232 in obesity and cardiometabolic risk factors, are expected throughout 2025.
Headline financials
Revenue & EPS history
Ventyx Biosciences · Revenue · Quarterly
$0
Forward guidance
Ventyx Biosciences anticipates multiple Phase 2 topline data readouts throughout 2025, including for VTX2735 in recurrent pericarditis and VTX3232 in obesity and cardiometabolic risk factors. The company expects its current cash, cash equivalents, and marketable securities to fund operations into at least H2 2026.
Tailwinds
- Expected topline data readouts from multiple Phase 2 studies throughout 2025, including VTX2735 in recurrent pericarditis in H2 2025.
- Expected topline data readouts for VTX3232 in participants with obesity and cardiometabolic risk factors in H2 2025.
- Anticipated completion of the Phase 2 biomarker study of VTX3232 in patients with early Parkinson's disease in Q2 2025.
- Current cash, cash equivalents, and marketable securities of $252.9 million are expected to fund operations into at least H2 2026.
- Exploring partnership opportunities for tamuzimod in ulcerative colitis and VTX958 in Crohn's disease.
Headwinds
- Potential for delays in the commencement, enrollment, and completion of clinical trials.
- Dependence on third parties for manufacturing, research, and preclinical/clinical testing.
- Disruptions in the supply chain, including raw materials and animal availability.
- Early clinical trial results may not be predictive of future outcomes.
- Regulatory developments in the United States and foreign countries could impact development or approval.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 8 quarterly earnings reports · overlaid with Q4 2024
+4.2%
Avg return
Earnings day
+7.1%
Avg return
5 days after
+13.8%
Avg return
30 days after
56%
10 / 18 earnings
Positive
+34.4%
Q2 2022
Best reaction
-11.9%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -5.7% | +2.5% | -6.0% | |
| Q2 2025 | +18.4% | +20.5% | +6.8% | |
| Q1 2025 | +7.0% | +1.8% | +113.2% | |
| Q4 2024 | +9.0% | +4.2% | -16.1% | |
| Q3 2024 | -5.6% | -10.0% | +34.2% | |
| Q2 2024 | +5.6% | -0.5% | +10.9% | |
| Q1 2024 | -7.9% | -6.3% | -26.4% | |
| Q4 2023 | +32.6% | +45.0% | -6.5% | |
| Q3 2023 | -11.9% | — | — | |
| Q2 2023 | +1.9% | — | — | |
| Q1 2023 | -11.6% | — | — | |
| Q4 2022 | -8.3% | — | — | |
| Q3 2022 | -9.1% | — | — | |
| Q2 2022 | +34.4% | — | — | |
| Q1 2022 | +10.6% | — | — | |
| Q2 2021 | +9.3% | — | — | |
| Q4 2021 | +9.3% | — | — | |
| Q3 2021 | -1.7% | — | — | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro